Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
A SQUARE

A confluence of investing in real estate, agriculture and bio-energy

Tuesday, April 15, 2008
Currently, we believe we are unique in that we intend to acquire and manage most of the land ourselves as opposed to essentially leasing it..

A SQUARE :: 15Apr08 A confluence of investing in real estate, agriculture and bio-energy
Category Hybrid
Author Sona Blessing
We believe this is a triple play - firstly, the long term trend for real estate prices is slated to rise - both at an absolute and relative level. ...
Download this research The many benefits of an A SQUARE subscription Recommend to a friend

<< A SQUARE archive sorted by date    << A SQUARE archive sorted by category

 Article link
More research related to Hybrid

[05Mar09] [Hybrid] A premium finance program through a zero coupon bond
The +7.2% yield is implied throughout the bond life until lump sum repayment on due date in year 10

Download

[04Nov08] [Hybrid] A fund of funds that invests globally in asset based lending, investing & other strategies
Loan tenure: ranges from 1 day to 3 years - with 34.1% ranging between 91-120 days

Download

[20Aug08] [Hybrid] A new-energy/hybrid fund
Fund allocates to public and private equity in the renewable and alternative energy space

Download

[20Feb08] [Hybrid] Hybrid engine strategy
This is the culmination of, and the strategy is based on volatility distribution studies

Download

[03Oct07] [Hybrid] Partners Group Alternative Investments Fund
A blended alternative investment product that features a combination of private equity, private debt and hedge funds investments

Download

[13Jun07] [Hybrid] Oceanic Small Cap Fund
Small cap IPOs provide potential for exceptional returns in excess of those generated by larger cap companies in the same sector

Download
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for